CO5280147A1 - MONOCLONAL HUMAN ANTIBODY - Google Patents

MONOCLONAL HUMAN ANTIBODY

Info

Publication number
CO5280147A1
CO5280147A1 CO00035406A CO00035406A CO5280147A1 CO 5280147 A1 CO5280147 A1 CO 5280147A1 CO 00035406 A CO00035406 A CO 00035406A CO 00035406 A CO00035406 A CO 00035406A CO 5280147 A1 CO5280147 A1 CO 5280147A1
Authority
CO
Colombia
Prior art keywords
nucleic acid
group
human monoclonal
human antibody
acid sequence
Prior art date
Application number
CO00035406A
Other languages
Spanish (es)
Inventor
Mitchel S Gross
Raymond W Sweet
Geraldine Taylor
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CO5280147A1 publication Critical patent/CO5280147A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus

Abstract

1.- Un anticuerpo monoclonal humano y fragmentos funcionales del mismo, específicamente reactivos con un epítope de la proteína F del virus sincitial respiratorio y capaces de neutralizar la infección causada por dicho virus, seleccionados del gru po constituido por G?-1A y G?-1B.5.- Una molécula aislada de ácido nucleico seleccionada del grupo constituido por:una secuencia de ácido nucleico que codifica alguno de los anticuerpos humanos monoclonales, anticuemos alterados y CDR de cualquiera de las reivindica ciones 1-4;un ácido nucleico complementario a cualquiera de las secuencias de (a); y una secuencia de ácido nucleico de 18 o más nucleótidos capaz de hibridarse con las CDR de cualquiera de las reivindicaciones 1-4, bajo condiciones estrictas.1.- A human monoclonal antibody and functional fragments thereof, specifically reactive with an epitope of the respiratory syncytial virus F protein and capable of neutralizing the infection caused by said virus, selected from the group consisting of G? -1A and G? -1B.5.- An isolated nucleic acid molecule selected from the group consisting of: a nucleic acid sequence encoding any of the human monoclonal antibodies, altered antibodies and CDR of any of claims 1-4; a complementary nucleic acid to any of the sequences of (a); and a nucleic acid sequence of 18 or more nucleotides capable of hybridizing with the CDRs of any of claims 1-4, under strict conditions.

CO00035406A 1999-05-18 2000-05-16 MONOCLONAL HUMAN ANTIBODY CO5280147A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13470299P 1999-05-18 1999-05-18

Publications (1)

Publication Number Publication Date
CO5280147A1 true CO5280147A1 (en) 2003-05-30

Family

ID=22464579

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00035406A CO5280147A1 (en) 1999-05-18 2000-05-16 MONOCLONAL HUMAN ANTIBODY

Country Status (6)

Country Link
EP (1) EP1178829A4 (en)
JP (1) JP2002543822A (en)
AR (1) AR030019A1 (en)
AU (1) AU5441000A (en)
CO (1) CO5280147A1 (en)
WO (1) WO2000069462A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4794301B2 (en) 2003-06-11 2011-10-19 中外製薬株式会社 Antibody production method
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
TW200722518A (en) 2005-03-31 2007-06-16 Chugai Pharmaceutical Co Ltd Sc(fv)2 structural isomers
JP5085322B2 (en) 2005-06-10 2012-11-28 中外製薬株式会社 Pharmaceutical composition containing sc (Fv) 2
JP5068167B2 (en) 2005-06-10 2012-11-07 中外製薬株式会社 Stabilizer for protein preparation containing meglumine and use thereof
EP1925319B1 (en) * 2005-06-10 2018-03-07 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(fv)2
ES2654040T3 (en) 2006-03-31 2018-02-12 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for the purification of bispecific antibodies
EP1997830A1 (en) * 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
DK2285408T3 (en) 2008-06-05 2019-02-04 Ablynx Nv AMINO ACID SEQUENCES AGAINST COATING PROTEINS IN A VIRUS AND POLYPEPTIDES INCLUDING THESE FOR TREATMENT OF VIRUSAL DISEASES
DK2438087T3 (en) * 2009-06-05 2017-08-28 Ablynx Nv TRIVALENT NANOBODY CONSTRUCTIONS AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (HRSV) FOR PREVENTION AND / OR TREATMENT OF AIR INFECTIONS
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
US9644022B2 (en) 2009-11-30 2017-05-09 Ablynx N.V. Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
TWI659968B (en) * 2013-03-14 2019-05-21 再生元醫藥公司 Human antibodies to respiratory syncytial virus f protein and methods of use thereof
BR112016006197B1 (en) 2013-09-27 2023-04-11 Chugai Seiyaku Kabushiki Kaisha METHOD FOR PRODUCING A BISPECIFIC POLYPEPTIDE ANTIBODY
JO3555B1 (en) 2015-10-29 2020-07-05 Merck Sharp & Dohme Antibody neutralizing human respiratory syncytial virus
WO2017115773A1 (en) 2015-12-28 2017-07-06 中外製薬株式会社 Method for promoting efficiency of purification of fc region-containing polypeptide

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
WO1994006448A1 (en) * 1992-09-16 1994-03-31 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
US6019980A (en) * 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
WO1998019704A1 (en) * 1996-11-01 1998-05-14 Smithkline Beecham Corporation Human monoclonal antibodies

Also Published As

Publication number Publication date
JP2002543822A (en) 2002-12-24
EP1178829A4 (en) 2005-06-08
AR030019A1 (en) 2003-08-13
AU5441000A (en) 2000-12-05
WO2000069462A1 (en) 2000-11-23
EP1178829A1 (en) 2002-02-13

Similar Documents

Publication Publication Date Title
CO5280147A1 (en) MONOCLONAL HUMAN ANTIBODY
US20180327800A1 (en) Monoclonal antibody production by ebv transformation of b cells
EP1597280B1 (en) Monoclonal antibody production by ebv transformation of b cells
HRP20171978T1 (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
AR038568A1 (en) ANTI-A BETA ANTIBODIES AND ITS USE
CO5580797A2 (en) ANTI-CD33 ANTIBODIES AND METHOD FOR TREATMENT OF ACUTE MYELOID LEUKEMIA USING THE SAME
CO5590973A2 (en) NUCLEIC ACID OF ADENOVIRUS DE SIMIO AND SEQUENCES OF AMINO ACIDS, VECTORS CONTAINING THE SAME AND METHODS OF USE
RS50157B (en) Neutralizing high affinity human monoclonal antibodies specific to rsv f-protein and methods for their manufacture
IL129299A0 (en) Monoclonal antibodies antigens and diagnosis of malignant diseases
PT690132E (en) ANTI-HIV MONOCLONAL ANTIBODY
HUP0002176A2 (en) Prrsv antigenic sites identifying peptide sequences of prrs virus for use in vaccines or diagnostic assays
DE60237778D1 (en) ANTIBODIES TO KDR, THEIR MANUFACTURE AND USES
RU2008100239A (en) THERAPEUTIC BINDING MOLECULES AS A CHIMERAL ANTIBODY
HK1071898A1 (en) Recombinant antibodies, and compositions and methods for making and using the same
WO2002036790A3 (en) Influenza virus vector for infection of dendritic cells
BR0211296A (en) Immunogenic peptide derived from subgroup a or b vrs protein g, nucleic acid sequence, pharmaceutical composition, polyclonal or monoclonal antibodies, diagnostic kit, use of an immunogenic peptide, and, conjugate
AR104906A1 (en) ANTIBODIES DIRECTED TO THE BONE MORPHOGENETIC PROTEIN 9 (BMP9) AND METHODS FROM THESE
WO1995021922A3 (en) Non-a, non-b, non-c, non-d, non-e hepatitis reagents and methods for their use
ATE234858T1 (en) ISOLATED AND SHORTENED NUCLEIC ACID MOLECULES CODING FOR GAGE TUMOR REJECTION ANTIGEN
DE60040136D1 (en) A NEW CHIMERIC PROTEIN FOR THE PREVENTION AND TREATMENT OF HIV INFECTION
DE69013132T2 (en) Process for the preparation of octa-2,7-dien-1-ol.
DE69836485D1 (en) HEPATITIS E-VIRUS FROM THE PIG AND ITS USES
AR002757A1 (en) OLIGONUCLEOTIDES SPECIFIC FOR HEPATITIS C VIRUSES, PHARMACEUTICAL COMPOSITION THAT CONTAIN THEM, USE OF SUCH OLIGONUCLEOTIDE, A KIT FOR THE DETECTION AND METHOD FOR SUCH DETECTION.
WO2001009290A3 (en) Avian infectious bronchitis virus serotype
KR101785909B1 (en) A composition for detecting undifferentiated human pluripotent stem cell, monoclonal antibody 6-1 and use thereof

Legal Events

Date Code Title Description
FA Application withdrawn